It was appointed by Medicxi, an independent European life sciences investment firm.
It’s planned that the new fund, ‘Medicxi Growth I’ will fill a late-stage funding gap in Europe by offering financial support to life sciences entrepreneurs.
Alex Di Santo, Director of Funds at Intertrust, commented: “We have enjoyed a solid relationship with Medicxi, including a successful partnership with Elian prior to its acquisition by Intertrust in 2016. We have a proven track record in providing quality client service and we look forward to continuing to work with Medicxi on this new fund. It’s good to see a fund of this nature being raised in the life sciences space and the positive social contribution they deliver.
“The high level of expertise and experience held within our funds team means we continue to broaden and strengthen our relationships with fund managers.”